August 29, 2016 6:03 PM ET

Biotechnology

Company Overview of Restorgenex Corporation

Company Overview

As of January 8, 2016, Restorgenex Corporation was acquired by Diffusion Pharmaceuticals LLC, in a reverse merger transaction. RestorGenex Corporation operates as a specialty biopharmaceutical company that focuses on developing products for ophthalmology, oncology, and dermatology. Its lead product is a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company’s pipeline also includes a “soft” anti-androgen compound for the treatment of acne vulgaris. The company was formerly known as Stratus Media Group, Inc. and changed its name ...

2150 East Lake Cook Road

Suite 750

Buffalo Grove, IL 60089

United States

8 Employees

Phone:

847-777-8092

Key Executives for Restorgenex Corporation

Restorgenex Corporation does not have any Key Executives recorded.

Restorgenex Corporation Key Developments

Restorgenex Corporation Announces Board Changes

In connection with the completion of the Merger and in accordance with the terms of the Merger Agreement, the Board of Directors of Restorgenex Corporation accepted the resignations from the Board of Directors and each of its committees of the following directors of the company, constituting all of the directors of the company prior to the Merger, with such resignations effective immediately prior to the effective time: Sol J. Barer, Ph.D., Isaac Blech, Rex Bright, Stephen M. Simes and Nelson K. Stacks. The Board of Directors also accepted the resignations of the following executive officers of the company, constituting all of the executive officers of the company prior to the Merger, with such resignations effective immediately prior to the Effective Time: Stephen M. Simes as Chief Executive Officer, Phillip B. Donenberg as Chief Financial Officer and Secretary, and Mark A. Weinberg, M.D. as Senior Vice President, Clinical Development. Also in connection with the completion of the Merger and in accordance with the terms of the Merger Agreement, the outgoing directors, prior to their resignation and in accordance with the company’s bylaws, fixed the number of directors at six, and appointed the following six individuals, constituting all of the directors of Diffusion prior to the Merger, to serve as directors of the Company, effective at the Effective Time and until the Company’s next annual meeting of stockholders, and until their respective successors are elected and qualified or until their earlier resignation or removal: David G. Kalergis, John L. Gainer, Thomas Byrne, Robert Adams, Mark T. Giles and Alan Levin. David G. Kalergis was appointed Chairman of the Board. Each of the new directors is entitled to participate in the company’s 2015 Equity Incentive Plan.

RestorGenex Corporation Announces Earnings Results for the Nine Months Ended September 30, 2015

RestorGenex Corporation announced earnings results for the nine months ended September 30, 2015. For the period, the company incurred a net loss of $20.7 million or $1.11 per share compared to net loss of $9.3 million or $0.76 per share for the same period last year. The primary reason for the increase in net loss was an $11.1 million non-cash impairment of goodwill during the period.

Restorgenex Corporation Presents at Dawson James Securities 2015 Growth Stock Conference, Oct-15-2015 11:15 AM

Restorgenex Corporation Presents at Dawson James Securities 2015 Growth Stock Conference, Oct-15-2015 11:15 AM. Venue: Wyndham Grand Hotel, Jupiter, Florida, United States.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
December 15, 2015
--
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Restorgenex Corporation, please visit www.restorgenex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.